Stoke Therapeutics, Inc. cotiza a 22.68 USD y tiene una capitalización bursátil de $1.5B. En los últimos 12 meses ha facturado $28M con un margen de flujo de caja libre del 24.4%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.93 | $-0.79 | $-0.97 |
| Estimado | $-0.91 | $-0.78 | $-0.82 | $-0.74 |
| Sorpresa | — | -19.2% | +3.7% | -31.1% |
| Métrica | STOK | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -11.2% | -38.6% | +27.5% |
| Net Margin | -3.7% | -33.6% | +29.8% |
| FCF Margin | 24.4% | -13.9% | +38.2% |
| ROE | -1.9% | -40.4% | +38.4% |
| ROA | -1.6% | -32.0% | +30.4% |
| Current Ratio | 5.28 | 2.84 | +2.44 |
| Debt / Equity | — | 0.28 | — |